🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Benjamin Kasenda

University of Basel

ORCID: 0000-0003-0110-8585

Also affiliated with University Hospital of Basel

MedicineDecision Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.899Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs

Trials(2018)10.1186/s13063-018-2877-z
Top 22%
0.899DataRank
Top 22%23 citations

Benjamin Speich, Florian Naudet, Arnav Agarwal, Francesco Sclafani, Juan Martin-Liberal +9 more

Papers

Driven by 6 papers — median percentile 78. Top paper: “Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016”.

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.24406
N/A
4.3DataRank · unranked
97 citations

Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal, Tiago V. Pereira +12 more

The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs

Trials(2018)10.1186/s13063-018-2877-z
Top 22%
0.899DataRank
Top 22%23 citations

Benjamin Speich, Florian Naudet, Arnav Agarwal, Francesco Sclafani, Juan Martin-Liberal +9 more

Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies

Journal of Clinical Epidemiology(2019)10.1016/j.jclinepi.2019.05.033
N/A
0.505DataRank · unranked
28 citations

Benjamin Speich, Matthias Briel, Francesco Sclafani, Heiner C. Bucher, Arnav Agarwal +5 more

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.04.11.439323
N/A
0.385DataRank · unranked
12 citations

Natália Rodrigues Mantuano, Nicole Kirchhammer, David E. Sanin, Jinyu Wang, Marcel P. Trefny +15 more

Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT)-rationale and design for an international collaborative study [study protocol].

BORIS (University Library Bern)(2020)10.7892/boris.146085
N/A
0DataRank · unranked
0 citations

Junhao Liu, Yu Jiang, Byron J. Gajewski, Cen Wu, Erik von Elm +20 more

CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL

Hematological Oncology(2023)10.1002/hon.3163_15
N/A
0DataRank · unranked
6 citations

Andrés J.M. Ferreri, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer +45 more